Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC): a double-blind, placebo-controlled, multicentre, randomised trial
ContributorsBaud, Olivier; Maury, Laure; Lebail, Florence; Ramful, Duksha; El Moussawi, Fatima; Nicaise, Claire; Zupan-Simunek, Véronique; Coursol, Anne; Beuchée, Alain; Bolot, Pascal; Andrini, Pierre; Mohamed, Damir; Alberti, Corinne; PREMILOC trial study group
Published inThe Lancet, vol. 387, no. 10030, p. 1827-1836
Publication date2016
Abstract
Keywords
- Anti-Inflammatory Agents/administration & dosage
- Bronchopulmonary Dysplasia/prevention & control
- Double-Blind Method
- Female
- France
- Humans
- Hydrocortisone/administration & dosage/analogs & derivatives
- Infant, Extremely Premature
- Infant, Newborn
- Logistic Models
- Male
- Treatment Outcome
Affiliation entities Not a UNIGE publication
Citation (ISO format)
BAUD, Olivier et al. Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC): a double-blind, placebo-controlled, multicentre, randomised trial. In: The Lancet, 2016, vol. 387, n° 10030, p. 1827–1836. doi: 10.1016/S0140-6736(16)00202-6
Main files (1)
Article (Published version)
Identifiers
- PID : unige:104560
- DOI : 10.1016/S0140-6736(16)00202-6
- PMID : 26916176
Journal ISSN0140-6736
